US Stock MarketDetailed Quotes
ACRS Aclaris Therapeutics
- 2.050
- -0.130-5.96%
Close Nov 15 16:00 ET
- 2.050
- 0.0000.00%
Post 17:13 ET
146.43MMarket Cap-3942P/E (TTM)
2.290High2.030Low736.03KVolume2.200Open2.180Pre Close1.56MTurnover1.33%Turnover RatioLossP/E (Static)71.43MShares2.72052wk High1.13P/B113.33MFloat Cap0.77052wk Low--Dividend TTM55.28MShs Float33.880Historical High--Div YieldTTM11.93%Amplitude0.590Historical Low2.118Avg Price1Lot Size
Aclaris Therapeutics Stock Forum
Sign in to post a comment
$Aclaris Therapeutics (ACRS.US)$ 4 hours ago when i posted this was 1,35 if you follow you know small profit but cheers and enjoy the weekend
2
$Aclaris Therapeutics (ACRS.US)$ nice move watch it
$Aclaris Therapeutics (ACRS.US)$
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics (NASDAQ: ACRS) has announced the dosing of the first patient in its Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, for treating moderate to severe atopic dermatitis. The open-label study aims ...
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics (NASDAQ: ACRS) has announced the dosing of the first patient in its Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, for treating moderate to severe atopic dermatitis. The open-label study aims ...
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million.
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...
$Aclaris Therapeutics (ACRS.US)$ big news
1
$Aclaris Therapeutics (ACRS.US)$
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million
$Aclaris Therapeutics (ACRS.US)$ There is a gap that needs fillin to 4.59, Now fill it you hussie! hehehe![]()
3
5
$Aclaris Therapeutics (ACRS.US)$ Reuters· 1 min ago1min
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
104807940 : how high do u think it will go
Teo knows OP 104807940 : Volume still good lets see